JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/60/0.1/16.05.25 | Market Closed - Börse Stuttgart 07:55:18 27/06/2024 BST | ||
| 0.048 EUR | -5.88% |
|
| Current month | +9.09% | ||
| 1 month | -12.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 0.048 | -5.88% |
| 26/06/24 | 0.051 | 0.00% |
| 25/06/24 | 0.051 | -1.92% |
| 24/06/24 | 0.052 | +20.93% |
| 21/06/24 | 0.043 | +13.16% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 07:55 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JB8U1D |
| ISIN | DE000JB8U1D3 |
| Date issued | 30/11/2023 |
| Strike | 60 $ |
| Maturity | 16/05/2025 (323 Days) |
| Parity | 10 : 1 |
| Emission price | 0.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.36 € |
|---|---|
| Lowest since issue | 0.038 € |
| Spread | 0.015 € |
| Spread % | 26.32% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.51
USD
Average target price
53.19
USD
Spread / Average Target
+28.15%
- Stock Market
- Warrants
- Warrant
